Euclidean Capital LLC reported 7 positions worth $36.61M for the quarter ended Jun 30, 2026, up 24.6% on the prior quarter. It opened 1 new position, added to 0, trimmed 0 and exited 0. Its largest holding is Oric Pharmaceuticals, Inc. at 29.3% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| TMS Teamshares Inc | +1.10M | – | $9.04M | 24.7% |
No positions were reduced this quarter.
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| TMS Teamshares Inc | +1.10M | $9.04M | 24.7% |
No positions were closed this quarter.
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | ORIC Oric Pharmaceuticals, Inc. | Healthcare | 989.4K | $10.72M | 29.27% | 0 | 0.0% | Unchanged | 0.92% |
| 2 | TMS Teamshares Inc | Financial Services | 1.10M | $9.04M | 24.7% | +1.10M | – | New | 2.11% |
| 3 | FHTX Foghorn Therapeutics Inc. | Healthcare | 1.57M | $7.68M | 20.98% | 0 | 0.0% | Unchanged | 2.23% |
| 4 | PMVP PMV Pharmaceuticals, Inc. | Healthcare | 2.63M | $3.52M | 9.62% | 0 | 0.0% | Unchanged | 4.92% |
| 5 | ALEC Alector, Inc. | Healthcare | 1.31M | $2.63M | 7.18% | 0 | 0.0% | Unchanged | 1.17% |
| 6 | SRZN Surrozen, Inc. | Healthcare | 87.7K | $2.28M | 6.22% | 0 | 0.0% | Unchanged | 0.75% |
| 7 | TNYA Tenaya Therapeutics, Inc. | Healthcare | 1.02M | $750.71K | 2.05% | 0 | 0.0% | Unchanged | 0.45% |
Tip. Select a row to see that position’s full history at Euclidean Capital.
As of its Q2 2026 13F filing, Euclidean Capital LLC’s five largest positions were Oric Pharmaceuticals, Inc. (ORIC) at 29.3%, Teamshares Inc (TMS) at 24.7%, Foghorn Therapeutics Inc. (FHTX) at 21.0%, PMV Pharmaceuticals, Inc. (PMVP) at 9.6%, Alector, Inc. (ALEC) at 7.2% of the reported portfolio.
Euclidean Capital LLC reported a 13F portfolio worth $36.61M across 7 positions for Q2 2026. That is up 24.6% from the previous quarter.
Its largest purchases by value were Teamshares Inc ($9.04M). It opened 1 new positions.
From the Form 13F-HR reports Euclidean Capital LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.